#United States #Salt Lake City #Co-Diagnostics #PCR Technology #South Asia

Co-Diagnostics Expands Its Market Reach in South Asia

In a move to bolster its presence in South Asia, Co-Diagnostics, Inc. (Nasdaq: CODX), a leader in molecular diagnostics, has signed a significant agreement with CoSara Diagnostics Pvt. Ltd. This partnership is aimed at significantly broadening CoSara's commercial and distribution territories to include the burgeoning markets of Bangladesh, Pakistan, Nepal, and Sri Lanka. This strategic decision positions Co-Diagnostics to tap into a staggering total addressable market (TAM) of roughly $13 billion, underscoring the immense growth potential in the region.

Enhancing Market Accessibility

CoSara, jointly owned by Co-Diagnostics and Ambalal Sarabhai Enterprises Limited (ASE Group), is poised to utilize this expansion to further promote the CoSara PCR Pro® point-of-care instrument and the SARAGENE® product line. As these products are prepared for commercialization, CoSara will work extensively to establish reliable distribution channels across these newly added territories. This involves assessing regulatory pathways, prioritizing customer segments, and connecting with regional distributors to ensure a streamlined entry into these markets.

Addressing Local Needs

Mohal Sarabhai, the CEO of CoSara, emphasizes the critical demand for efficient and reliable diagnostics in South Asia, stating, "The region has a pressing need for accessible, quick, and non-invasive testing solutions." By expanding its operational footprint, Co-Diagnostics is set to build essential relationships with local partners, positioning itself to meet the growing needs for molecular tests targeting prevalent health issues like tuberculosis, HPV, and respiratory infections.

Strategic Vision for Growth

Co-Diagnostics CEO, Dwight Egan, stated, "This expansion aligns with our overarching strategy to set up regional infrastructure prior to product launch. We aim to create local manufacturing and distribution networks in key areas including the U.S., South Asia, as well as the Middle East and North Africa, ensuring that our PCR point-of-care platform remains scalable and primed for global deployment."

The company is planning a comprehensive approach to its market entry strategy, which includes hosting a virtual information session for potential distributors in the second quarter of 2026, followed by an in-person meeting later in the summer. Anyone interested in participating can reach out via email to gather more information.

Future Considerations

The Co-Dx PCR platform, which encompasses the PCR Home®, PCR Pro®, and related tests, is still subject to regulatory review, emphasizing the company's commitment to safety and efficacy before rolling out its products. As of now, these offerings are not available for sale.

As Co-Diagnostics embarks on this promising journey, the company's dedication to expanding into dynamic markets like South Asia reflects a commitment to improving healthcare accessibility and quality through innovative diagnostic solutions.

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc., based in Utah, develops, manufactures, and markets cutting-edge diagnostic technologies that focus on the detection and analysis of nucleic acid molecules such as DNA and RNA. Utilizing proprietary technology, the company aims to create tailored diagnostics for applications beyond infectious diseases.

Conclusion

The expansion into South Asia represents not just increased market opportunities for Co-Diagnostics but also a significant potential impact on public health in the region. As the company moves forward, it will be crucial to navigate the complexities of regulatory approvals and market entry strategies effectively, paving the way for enhanced healthcare solutions across diverse populations.